On April 1, 2019, the Health Resources and Services Administration implemented its long-delayed final rule on 340B ceiling price transparency, releasing a database reporting the maximum price drug manufacturers may charge covered entities for 340B drugs. Several hospital groups had filed a lawsuit to force HRSA to take action, which was voluntarily dismissed following the website’s launch.